Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease

Brian A. Lawlor; Linda M. Bierer; Theresa M. Ryan; James Schmeidler; Peter J. Knott; Lizette L. Williams; Richard C. Mohs; Kenneth L. Davis

doi:10.1016/0006-3223(94)00259-6

Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease

Brian A. Lawlor, Linda M. Bierer, Theresa M. Ryan, James Schmeidler, Peter J. Knott, Lizette L. Williams, Richard C. Mohs, Kenneth L. Davis

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Postmortem findings point to significant abnormalities in central noradrenergic function in Alzheimer's disease (AD) which may be associated with changes in peripheral markers. In this study, the relationship between the peripheral noradrenergic marker, plasma 3-methoxy-4-hydroxyphenylglycol (MHPG), and clinical symptoms was examined in 23 patients with probable AD. Basal MHPG levels correlated significantly with increased cognitive impairment (r = .58, p = .005), controlling for age, age at onset, gender, and time interval between plasma MHPG determination and cognitive testing. These results suggest that plasma MHPG increases as cognitive function in AD deteriorates, further supporting preliminary evidence for increases in noradrenergic indices in association with disease severity in AD.

Original language	English
Pages (from-to)	185-188
Number of pages	4
Journal	Biological Psychiatry
Volume	38
Issue number	3
DOIs	https://doi.org/10.1016/0006-3223(94)00259-6
State	Published - 1 Aug 1995
Externally published	Yes

Keywords

Alzheimer's disease
clinical symptoms
plasma MHPG

Access to Document

10.1016/0006-3223(94)00259-6

Cite this

@article{53dcaf8454d54b91928792557f18186c,

title = "Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease",

abstract = "Postmortem findings point to significant abnormalities in central noradrenergic function in Alzheimer's disease (AD) which may be associated with changes in peripheral markers. In this study, the relationship between the peripheral noradrenergic marker, plasma 3-methoxy-4-hydroxyphenylglycol (MHPG), and clinical symptoms was examined in 23 patients with probable AD. Basal MHPG levels correlated significantly with increased cognitive impairment (r = .58, p = .005), controlling for age, age at onset, gender, and time interval between plasma MHPG determination and cognitive testing. These results suggest that plasma MHPG increases as cognitive function in AD deteriorates, further supporting preliminary evidence for increases in noradrenergic indices in association with disease severity in AD.",

keywords = "Alzheimer's disease, clinical symptoms, plasma MHPG",

author = "Lawlor, {Brian A.} and Bierer, {Linda M.} and Ryan, {Theresa M.} and James Schmeidler and Knott, {Peter J.} and Williams, {Lizette L.} and Mohs, {Richard C.} and Davis, {Kenneth L.}",

year = "1995",

month = aug,

day = "1",

doi = "10.1016/0006-3223(94)00259-6",

language = "English",

volume = "38",

pages = "185--188",

journal = "Biological Psychiatry",

issn = "0006-3223",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease

AU - Lawlor, Brian A.

AU - Bierer, Linda M.

AU - Ryan, Theresa M.

AU - Schmeidler, James

AU - Knott, Peter J.

AU - Williams, Lizette L.

AU - Mohs, Richard C.

AU - Davis, Kenneth L.

PY - 1995/8/1

Y1 - 1995/8/1

N2 - Postmortem findings point to significant abnormalities in central noradrenergic function in Alzheimer's disease (AD) which may be associated with changes in peripheral markers. In this study, the relationship between the peripheral noradrenergic marker, plasma 3-methoxy-4-hydroxyphenylglycol (MHPG), and clinical symptoms was examined in 23 patients with probable AD. Basal MHPG levels correlated significantly with increased cognitive impairment (r = .58, p = .005), controlling for age, age at onset, gender, and time interval between plasma MHPG determination and cognitive testing. These results suggest that plasma MHPG increases as cognitive function in AD deteriorates, further supporting preliminary evidence for increases in noradrenergic indices in association with disease severity in AD.

AB - Postmortem findings point to significant abnormalities in central noradrenergic function in Alzheimer's disease (AD) which may be associated with changes in peripheral markers. In this study, the relationship between the peripheral noradrenergic marker, plasma 3-methoxy-4-hydroxyphenylglycol (MHPG), and clinical symptoms was examined in 23 patients with probable AD. Basal MHPG levels correlated significantly with increased cognitive impairment (r = .58, p = .005), controlling for age, age at onset, gender, and time interval between plasma MHPG determination and cognitive testing. These results suggest that plasma MHPG increases as cognitive function in AD deteriorates, further supporting preliminary evidence for increases in noradrenergic indices in association with disease severity in AD.

KW - Alzheimer's disease

KW - clinical symptoms

KW - plasma MHPG

UR - http://www.scopus.com/inward/record.url?scp=0029092418&partnerID=8YFLogxK

U2 - 10.1016/0006-3223(94)00259-6

DO - 10.1016/0006-3223(94)00259-6

M3 - Article

C2 - 7578662

AN - SCOPUS:0029092418

SN - 0006-3223

VL - 38

SP - 185

EP - 188

JO - Biological Psychiatry

JF - Biological Psychiatry

IS - 3

ER -

Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this